A Responsive Biomimetic Nanoagonist for Pyroptosis Induction and Controlled Resiquimod Release to Enhance Tumor Photoimmunotherapy.
The designed nanoagonist HBSA@CR offers a biomimetic platform for combined photo-immunotherapy, which achieves controlled R848 release while inducing tumor cell pyroptosis, reprogramming the immunosuppressive TME, and eliciting durable antitumor immunological memory.